Investors are starting to bet big on psychedelic medicine…
Private investment in the space needs to be coupled with research into their social impact…
Liana Gillooly, a development officer at MAPS, a non-profit investigating the therapeutic uses of psychedelics, with an early focus on MDMA as a potential treatment for PTSD. But Gillooly said that funding needs to be set aside for “safe contexts” for these treatments to be administered, and not just for-profit drug development… [After-all] ATAI’s funding, which totals $43 million, comes from Michael Auerbach’s New York-based Subversive Capital, but also includes investors ranging from Apeiron Investment Group, which is Angermayer’s family office; Bail Capital, a private equity firm; and Efrem Kamen, founder of the health care fund Pura Vida Investments. Prior investors include billionaire investor Mike Novogratz and the Icelandic businessman Thor Bjorgolfsson.
Original Article (CNBC)
Investors are starting to bet big on psychedelic medicine
Artwork Fair Use: epSos.de